SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS

被引：0
|
作者：
Coates, L. [1 ]
Strober, B. [2 ,4 ]
Yu, J. [3 ,5 ]
Leibowitz, E. [6 ]
Rowland, K. [6 ]
Kollmeier, A. [5 ]
Miller, M. [3 ,5 ]
Wang, Y. [3 ]
Li, S.
Chakravarty, S. D. [4 ,8 ]
Chan, D. [8 ]
Shawi, M.
Yang, Y. W. [7 ]
Lebwohl, M. [9 ,10 ]
Rahman, P. [11 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed, Rheumatol & Musculoskeletal Sci, Oxford, England
[2] Yale Univ, Dept Dermatol, New Haven, CT USA
[3] Cent Connecticut Dermatol Res, Dept Dermatol, Cromwell, CT USA
[4] Janssen Res & Dev LLC, Immunol, Spring House, CA USA
[5] Janssen Res Dev LLC, Dept Immunol, Horsham, PA USA
[6] Janssen Sci Affairs LLC, Dept Immunol, Spring House, PA USA
[7] Janssen Sci Affairs LLC, Dept Immunol, Horsham, PA USA
[8] Drexel Univ, Div Rheumatol, Coll Med, Philadelphia, PA USA
[9] Pharmaceut Co Johnson Johnson, Immunol Global Med Affairs, Horsham, PA USA
[10] Icahn Sch Med, Dept Dermatol, New York, NY USA
[11] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Safety; Psoriatic arthritis;
D O I：
10.1136/annrheumdis-2023-eular.1917
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1538
引用
收藏
页码：1134 / 1135
页数：2
相关论文
共 50 条
  • [1] SAFETY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2 AND 3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
    Strober, Bruce
    Coates, Laura
    Yu, Jenny
    Rowland, Katelyn
    Leibowitz, Evan
    Miller, Megan
    Kollmeier, Alexa
    Li, Shu
    Wang, Yanli
    Chan, Daphne
    Chakravarty, Soumya
    Yang, Ya-Wen
    Shawi, May
    Lebwohl, Mark
    Rahman, Proton
    [J]. RHEUMATOLOGY, 2023, 62
  • [2] Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
    Strober, Bruce
    Coates, Laura
    Yu, Jenny
    Rowland, Katelyn
    Leibowitz, Evan
    Miller, Megan
    Kollmeier, Alexa
    Li, Shu
    Wang, Yanli
    Chan, Daphne
    Chakravarty, Soumya
    Yang, Ya-Wen
    Shawi, May
    Lebwohl, Mark
    Rahman, Proton
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4199 - 4202
  • [3] Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
    Bruce Strober
    Laura C. Coates
    Mark G. Lebwohl
    Atul Deodhar
    Evan Leibowitz
    Katelyn Rowland
    Alexa P. Kollmeier
    Megan Miller
    Yanli Wang
    Shu Li
    Soumya D. Chakravarty
    Daphne Chan
    May Shawi
    Ya-Wen Yang
    Diamant Thaҫi
    Proton Rahman
    [J]. Drug Safety, 2024, 47 : 39 - 57
  • [4] Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
    Strober, Bruce
    Coates, Laura C.
    Lebwohl, Mark G.
    Deodhar, Atul
    Leibowitz, Evan
    Rowland, Katelyn
    Kollmeier, Alexa P.
    Miller, Megan
    Wang, Yanli
    Li, Shu
    Chakravarty, Soumya D.
    Chan, Daphne
    Shawi, May
    Yang, Ya-Wen
    Thaci, Diamant
    Rahman, Proton
    [J]. DRUG SAFETY, 2024, 47 (01) : 39 - 57
  • [5] INTEGRATED SAFETY DATA ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Husni, M. E.
    Schwartzman, S.
    Deodhar, A.
    Kafka, S.
    Chakravarty, S. D.
    Hsia, E. C.
    Harrison, D. D.
    Leu, J. H.
    Zhou, Y.
    Lo, K. H.
    Kavanaugh, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 608 - 609
  • [6] An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn's Disease, and Psoriasis
    Gensler, Lianne S.
    Hsia, Elizabeth C.
    Gasink, Christopher
    Randazzo, Bruce
    Parenti, Dennis
    Fakharzadeh, Steve
    Tang, Kehzen L.
    Chakravarty, Soumya
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
    Gordon, Kenneth
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2791 - 2793
  • [8] AN INTEGRATED SAFETY DATA ANALYSIS ACROSS ALL PHASE II AND PHASE III CLINICAL PROGRAMS FOR USTEKINUMAB IN PSORIATIC ARTHRITIS, CROHN'S DISEASE, AND PSORIASIS
    Gensler, L. S.
    Hsia, E.
    Gasink, C.
    Randazzo, B.
    Parenti, D.
    Fakharzadeh, S.
    Gao, L. -L.
    Chakravarty, S. D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 950 - 950
  • [9] CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    McInnes, Iain
    Helliwell, Philip
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Xu, Xie L.
    Xu, Stephen
    Wang, Yuhua
    Hsia, Elizabeth C.
    Deodhar, Atul
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1277 - 1278
  • [10] Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
    Ritchlin, Christopher T.
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya D.
    Rampakakis, Emmanouil
    Shawi, May
    Schiopu, Elena
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul
    [J]. CLINICAL RHEUMATOLOGY, 2024, 43 (08) : 2551 - 2563
12345